Nicotinamide riboside has been studied in 650 papers since 1987: 67 trials and 16 observational studies in people, 316 in animals, 93 in cells, 133 reviews; 129 in the past year. The newest story, Nov 9, 2026: “High-fat diet triggers irregular heart rhythms in altered mice”.
Get new research on nicotinamide riboside by email
At a glance
Nicotinamide riboside extends yeast lifespan across independent labs; human trials report increased blood NAD+ but no clear cognitive effect. Mouse inflammation results point both ways. There are 33 registered aging trials; across all uses, 12 trials ended over a year ago without posted results, while 13 of 57 human papers declare ties to developers Niagen Bioscience and Elysium Health.
1,271 findings in 432 papers from 1989 to 2026, 49 of them since April 2026
Independent labs found the same change in cells, worms or flies, mice and people. 172 independent labs in 34 countries; 75 trials, 37 about aging, 12 with no results posted.
“yielding an adjusted mean difference of 2.72 points (95% CI, 0.47-4.98 points; P = .02), favoring placebo.”
Cells, worms or flies, mice and humans: replicated by independent labs.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
172 independent labs in 34 countries
58 findings against
75 trials, 37 about aging, 12 with no results posted
Studies of nicotinamide riboside measured 545 outcomes; the most studied are NAD+ (51 studies), inflammation (26) and oxidative stress and ROS signaling (17).
Nicotinamide riboside increases NAD+ in humans following the first injection (9.5, 8.8, 11.1, and 15.1% average increases).
“A total of 38/39 participants demonstrated an increase in NAD+ during at least one time point assessed following the first injection, resulting in 9.5, 8.8, 11.1, and 15.1% average increases in the 50 mg IM, 50 mg SC, 100 mg IM, and 100 mg SC groups, respectively.”
Human trialfollowing the first injectionthree consecutive daysn = 39
“an average of the daily percentage increases in NAD+ was consistent across treatment groups”
Human trialIntramuscular or subcutaneous administration; no placebo grouppharmaceutical-grade injectable NRwhole blood50 or 100 mg daily3 consecutive daysn = 39
Nicotinamide riboside increases NAD+ in humans (twofold).
“Consistent with prior studies of NR supplementation reporting an increase in NAD+ metabolites or catabolites,,,,, we observed a robust increase in blood NAD+ concentration in the NR group compared to placebo, with levels nearly doubling from baseline.”
Alzheimer's & dementia : the journal of the Alzheimer's Association·
Nicotinamide riboside increases NAD+ in humans.
“In the pooled cohort, blood NAD levels increased significantly over time during treatment (LME, p = 1.30x10−9) and a decline during washout (LME, p = 6.51x10−13).”
Nicotinamide riboside increases NAD+ in humans (NAD+ 23.36 to 48.52 μM with NR vs 24.12 to 25.14 μM with placebo; treatment by time interaction p<0.001).
“Blood NAD + increased with NR (pre: 23.36 ± 1.94; post: 48.52 ± 4.12 μM) compared with placebo”
Nicotinamide riboside increases NAD+ in humans (71.1 μM (95% CI 57.2–85.0 μM) vs no change).
“Six weeks of oral supplementation with NR increased NAD+ levels in whole blood by 71.1 μM (95% CI 57.2–85.0 μM) in patients with COPD and by 49.4 μM (95% CI 30.9–68.0 μM) in lung-healthy controls, with no change for placebo.”
Nicotinamide riboside increases NAD+ in humans (0.065 mM (~16%) higher).
“On average, cerebral NAD+ levels were 0.065 mM (~16%) higher after taking the NR supplement, which was significant compared to baseline (t(8)=5.93, p<0.001).”
↓downin mice17↓downin rats2↓downin humans1↓downin M. amblycephala cells1+5
26 studies
Nicotinamide riboside decreases inflammation in mice (myocardial infarction).
“Mechanistically, NR protection converged on the SIRT1–p65 axis, limiting ferroptotic and inflammatory injury while preserving mitochondrial function.”
Nicotinamide riboside decreases inflammation in mice (heat exposure).
“This effect is associated with anti-inflammatory and antioxidative activities, mitochondrial protection, and anti-apoptosis without NAD+ homeostatic alterations.”
Animalsheat exposureskeletal muscle185 mg/kg body weight daily10 daysfemales
Nicotinamide riboside decreases inflammation in db/db mice.
“NR attenuated markers of inflammation, including astrocytosis and microglial activation, activation of inflammatory signaling via STING and NF-kB, and pro-inflammatory cytokines.”
↓downin mice7↓downin human cells2↓downin mouse cells2↓downin rats2+4
17 studies
Nicotinamide riboside decreases oxidative stress and ROS signaling in mice (heat exposure).
“This effect is associated with anti-inflammatory and antioxidative activities, mitochondrial protection, and anti-apoptosis without NAD+ homeostatic alterations.”
Animalsheat exposureskeletal muscle185 mg/kg body weight daily10 daysfemales
Nicotinamide riboside decreases oxidative stress and ROS signaling in endothelial cells treated with patient sera.
“NAD+ supplementation with NR was associated with reduced oxidative stress and increased nitric oxide production and mitochondrial efficiency in endothelial cells treated with patient sera.”
Cellsin endothelial cells treated with patient seracerebromicrovascular endothelial cells4 weeks
↓downin mice5↓downin cells3↓downin human cells2↓downin mouse cells2+3
15 studies
Nicotinamide riboside decreases apoptosis in mice (heat exposure).
“This effect is associated with anti-inflammatory and antioxidative activities, mitochondrial protection, and anti-apoptosis without NAD+ homeostatic alterations.”
Animalsheat exposureskeletal muscle185 mg/kg body weight daily10 daysfemales
Nicotinamide riboside decreases apoptosis in M. amblycephala cells (high-glucose-treated hepatocytes, compared with NA, NAM and NMN).
“NR presented distinct and superior effects in terms of anti-oxidative stress, inflammation inhibition, and anti-apoptosis compared with NA, NAM, and NMN.”
Cellshigh-glucose-treated hepatocytes, compared with NA, NAM and NMNhepatocytes
Nicotinamide riboside increases SIRT1 in cells (glutamate-induced decrease in SIRT1 protein expression).
“NR also restored the decreased protein expression of sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) induced by glutamate.”
Cellsglutamate-induced decrease in SIRT1 protein expression
The Journal of pharmacology and experimental therapeutics·
Nicotinamide riboside showed no clear effect on cognitive function in humans.
“As for the primary analysis (between‐group comparison during the first 8 weeks), there were no differences in the RBANS total scaled score (p = 0.55), nor for the five subdomains.”
Human trialtwo consecutive 8-week treatment periodsn = 46
Nicotinamide riboside decreases cellular senescence in mice.
“In aged male mice, two months of NR or NRH treatment suppressed senescence markers, improved diastolic function, and reduced hypertrophy and fibrosis.”
Nicotinamide riboside improves mitochondrial function in mice (experimental colitis).
“Treatment of mice undergoing experimental colitis with an NAD+ precursor reduced the severity of colitis, restored mitochondrial function, and increased active PGC1α levels”
Nicotinamide riboside increases autophagy in chronic cerebral hypoperfusion rats, where CCH impaired flux.
“NR may maintain mitochondrial structural integrity and exert a protective role by attenuating mitochondrial fission and impaired autophagy flux caused by CCH.”
Nicotinamide riboside increases autophagy in Rev1-/- MEFs.
“Autophagy decreases in Rev1-/- mouse embryonic fibroblasts (MEFs) and can be restored by supplementing the NAD+ precursor nicotinamide riboside (NR).”
Alzheimer's & dementia : the journal of the Alzheimer's Association·
Nicotinamide riboside increases blood NAD+ concentration in humans (measured by dried blood spot analysis) (peak +20.7% relative to baseline).
“NR IV appeared to promote the most robust increases in NAD+ concentration as measured by dried blood spot analyses, with peak NAD+ levels increasing by 20.7% relative to baseline”
Human trialmeasured by dried blood spot analysisintravenous500 mg
Nicotinamide riboside showed no clear effect on adverse events in humans (bolus injections).
“Both NR and NAD+ injections were well-tolerated, as no participants withdrew from discomfort or other injection-related concerns, nor were any reported severe or unexpected adverse events attributable to the test materials.”
Human trialbolus injectionsthree consecutive daysn = 45
Nicotinamide riboside increases Bioenergetic Health Index in humans (compared with placebo, in monocytes) (estimated difference 0.29 (95% CI 0.06 to 0.53)).
“NR, but not CoQ10, increased the Bioenergetic Health Index (estimated difference, 0.29; 95% CI, 0.06 to 0.53)”
Human trialcompared with placebo, in monocytesmonocytes1000 mg/dsix weeksn = 14
Clinical journal of the American Society of Nephrology : CJASN·
Nicotinamide riboside increases Bioenergetic Health Index in monocytes compared with placebo (estimated mean difference of 0.29, 95% CI 0.06 to 0.53).
“NR supplementation significantly increased monocyte spare respiratory capacity by an estimated mean difference of 3.52 (95% CI, 0.04 to 7.0 pmol/min per 10,000 cells, P = 0.04) and BHI, an index representing mitochondrial function by an estimated mean difference of 0.29 (95% CI, 0.06 to 0.53; P = 0.02) compared with placebo (Figure and Table”
Human trialin monocytes compared with placebotabletsmonocytes6-week durationn = 14
Clinical journal of the American Society of Nephrology : CJASN·
Nicotinamide riboside increases Bioenergetic Health Index in humans (monocytes, versus placebo, subsample of participants) (estimated difference 0.29 (95% CI 0.06 to 0.53)).
“NR, but not CoQ10, increased the bioenergetic health index (BHI) (estimated difference, 0.29, 95% CI of 0.06 to 0.53)”
Human trialmonocytes, versus placebo, subsample of participantsmonocytes1000 mg/daysix weeksn = 14
Studies link nicotinamide riboside with 10 measures, among them post-injection pain and muscle soreness/tightness, mortality and oxidative phosphorylation.
Post-injection pain and muscle soreness/tightness
↑upin humans1
1 study
Nicotinamide riboside is associated with post-injection pain and muscle soreness/tightness in humans (post-injection) (44% and 41%).
“The pooled response frequency noted “pain more than two minutes post-injection” as the most frequently described observation (44%), followed by muscle soreness/tightness (41%) and itching (31%).”
Human trialpost-injectionthree consecutive daysn = 39
Nicotinamide riboside is associated with post-injection pain and muscle soreness/tightness in humans (Reported more than two minutes after intramuscular or subcutaneous injection) (Pain: 44%; muscle soreness/tightness: 41%).
“Pain and muscle soreness/tightness more than two minutes after the injection were reported by 44% and 41% of the participants, respectively”
Human trialReported more than two minutes after intramuscular or subcutaneous injectionpharmaceutical-grade injectable NR50 or 100 mg daily3 consecutive daysn = 39
Nicotinamide riboside is associated with oxidative phosphorylation in POLG organoids.
“NR treatment was associated with altered expression of genes involved in oxidative phosphorylation, NADH dehydrogenase activity, respiratory chain assembly, and synaptic pathways.”
Nicotinamide riboside is associated with oxidative phosphorylation co-expression modules (brain-area specific effects).
“We observed brain-area specific effects of NR on co-expressed protein modules of oxidative phosphorylation, fatty acid oxidation, and neurotransmitter regulation pathways, which correlated with RSI components.”
Completed the pilot study and grant funding not obtained to continue to the main phase 2 study. The pilot study did not show a statistical significance in the primary or secondary outcome measures.
Nicotinamide riboside extends yeast lifespan across independent labs; human trials report increased or unchanged NAD+ and unchanged cognition. Mouse inflammation changes point both ways, with increases independently replicated. Registrations include 23 aging-related trials; across uses, 12 trials ended over a year ago without posted results or citing papers, and 14 of 51 human papers declare developer ties.
Independent labs report longer yeast lifespan with nicotinamide riboside; a mouse study reports longer lifespan in females lacking cardiac REV-ERBs. Human studies report increased NAD+ or no change, and independent labs report increased mouse inflammation. Fifteen registered trials concern aging; 13 trials across uses have no results posted over a year after ending; 10 human papers declare ties to its developers.
Summary rewritten as its findings changed.
As it read before
Independent labs report yeast lifespan extension and higher mouse NAD+ with nicotinamide riboside; human trials report higher NAD+, though mouse and human studies also report no change. An early Parkinson disease trial reports increased nonmotor symptom scores versus placebo. Fifteen registered trials concern aging; 13 trials across uses ended over a year ago without posted results or citing papers; human papers declare developer ties.
Summary rewritten as its findings changed.
As it read before
Nicotinamide riboside extends yeast lifespan across independent labs; mouse studies report lifespan extension or no change. Human trials report higher NAD+ but unchanged cognition; an early Parkinson disease trial favors placebo on symptom scores. Eleven registered trials concern aging; across all uses, 13 lack posted results over a year after ending, companies sponsor 11, and company-affiliated authors contribute to 13 findings.
Summary rewritten as its findings changed.
As it read before
One mouse preprint reports that nicotinamide riboside increases NAD+ and decreases mitochondrial reactive oxygen species and CD38 in CD8-positive T cells during T. cruzi infection, while reducing parasitemia and skeletal muscle parasite burden during acute infection.
Nearly 100% of genetically susceptible mice developed the irregular heartbeat on a high-fat diet, offering a model for studying metabolic changes.Nearly 100% of genetically susceptible mice developed the irregular heartbeat on a high-fat diet, offering a model for studying metabolic changes.